DAY ONE BIOPHARMACEUTICALS INC. - COMMON STOCK

Day One Reports First Quarter 2025 Financial Results and Corporate Progress

06 5 2025 13:01:00 提供 Nasdaq GlobeNewswire

Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025

22 4 2025 05:29:59 提供 Nasdaq GlobeNewswire

Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress

25 2 2025 13:05:00 提供 Nasdaq GlobeNewswire

Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025

11 2 2025 05:30:00 提供 Nasdaq GlobeNewswire

Day One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate Priorities

13 1 2025 05:00:01 提供 Nasdaq GlobeNewswire

Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference

17 12 2024 05:30:34 提供 Nasdaq GlobeNewswire

Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development

20 11 2024 13:30:00 提供 Nasdaq GlobeNewswire

Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference

18 11 2024 05:30:00 提供 Nasdaq GlobeNewswire

Day One Reports Third Quarter 2024 Financial Results and Corporate Progress

30 10 2024 13:01:00 提供 Nasdaq GlobeNewswire

Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024

16 10 2024 05:30:00 提供 Nasdaq GlobeNewswire

Day One Reports Second Quarter 2024 Financial Results and Corporate Progress

30 7 2024 04:30:00 提供 Nasdaq GlobeNewswire

Day One Announces Oversubscribed $175.0 Million Private Placement

30 7 2024 04:00:00 提供 Nasdaq GlobeNewswire

Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers

18 6 2024 05:30:00 提供 Nasdaq GlobeNewswire

Day One Announces Sale of Priority Review Voucher for $108 Million

30 5 2024 05:30:00 提供 Nasdaq GlobeNewswire

Day One Reports First Quarter 2024 Financial Results and Corporate Progress

06 5 2024 13:30:00 提供 Nasdaq GlobeNewswire

Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor

23 4 2024 12:56:39 提供 Nasdaq GlobeNewswire

Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress

26 2 2024 13:30:00 提供 Nasdaq GlobeNewswire

Day One Announces Two New Appointments to Board of Directors

17 1 2024 05:00:00 提供 Nasdaq GlobeNewswire

Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference

19 12 2023 05:00:00 提供 Nasdaq GlobeNewswire

Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine

17 11 2023 04:00:00 提供 Nasdaq GlobeNewswire